At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 277 enrolled
Drug / intervention
Nebivolol +1 moredrug
Likely dose
Nebivolol 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Prospective, Randomized, Double-blind, Placebo-Controlled, Dose-Titration Study of Nebivolol Monotherapy in Hispanic Patients With Stage 1 or Stage 2 Hypertension
In Brief
A Phase 4 clinical trial evaluating Nebivolol and Placebo for Hypertension. Completed, enrolled 277 participants across 32 sites in 2 countries.
Detailed Summary
This study will evaluate the efficacy and safety of nebivolol monotherapy in Hispanic patients with stage 1 or stage 2 hypertension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedOct 2008
Primary CompletionNov 2009
TodayJul 2026
First PostedOct 10, 2008
Enrollment StartSep 1, 2008
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.7 years ago
Interventions
Nebivololdrug
Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets , oral administration Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
Placebodrug
Matching placebo tablets, oral administration